|
A PHASE III TRIAL FOR OPTIMALLY DEBULKED, ADVANCED ENDOMETRIAL CANCER
Summary
Study for patients who are optimally debulked with either surgical stage III or IVA endometrial cancer, including clear cell and serous papillary and undifferentiated carcinoma..
Description
Patients with endometrial cancer have been treated with radiation and chemotherapy. Today most women with endometrial cancer whose cancer has spread outside the uterus generally receive chemotherapy. Women who have disease outside the uterus may also receive radiation to the areas where the disease has spread. It is not clear whether giving chemotherapy alone or together with radiation is the best treatment. This study is being conducted to determine if radiation therapy combined with chemotherapy administered for a total of 4 cycles offers a benefit over chemotherapy alone administered over 6 cycles.
Inclusion/exclusion
To be eligible for this study, patients must meet several criteria, including but not limited to the following: Must be 18 years old and have stage III or IVA endometrial cancer Cannot have recurrent endometrial cancer or received prior chemotherapy for endometrial cancer Entry into study no greater than 8 weeks from surgery
Principal Investigator
Jeannine Villella, D.O.
Department
Gynecology/Oncology
Email
jlbrown@winthrop.org
Other Contact
For more information please contact Jennifer Brown, Research Coordinator, at 516-663-3115.
|
